AHNAK2 Urinary Protein Expression as Potential Biomarker for Bladder Cancer Detection: A Pilot Study

Area of Science:

• Urology
• Oncology
• Biomarker Discovery

Background:

• Bladder cancer diagnosis and surveillance often rely on invasive procedures like cystoscopy.
• Novel, non-invasive biomarkers are needed to improve patient management and reduce healthcare costs.

Purpose of the Study:

• To measure urinary levels of the AHNAK2 protein in patients with bladder cancer.
• To evaluate AHNAK2 as a potential biomarker for bladder cancer detection and surveillance.

Main Methods:

• A prospective case-control study involving 67 participants (37 bladder cancer, 30 controls).
• Urine samples were collected and analyzed using enzyme-linked immunosorbent assay (ELISA).
• Statistical analyses included t-tests, correlation, and receiver operating curve (ROC) analysis.

Main Results:

• Mean urinary AHNAK2 levels were significantly higher in bladder cancer patients (49.08 pg/mL) compared to controls (5.28 pg/mL).
• Elevated levels were observed in both non-invasive and invasive bladder cancers, with significantly higher levels in muscle-invasive disease.
• The assay demonstrated a sensitivity of 64.19% and specificity of 66.67%, with an area under the curve of 0.695.

Conclusions:

• Urinary AHNAK2 protein shows potential as a biomarker for bladder cancer surveillance.
• Incorporating AHNAK2 levels into stratification nomograms could potentially decrease the need for frequent cystoscopies.